Amniotics AB (OSTO:AMNI) Cash-to-Debt : No Debt ⁽¹⁾ (As of Sep. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Amniotics AB Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Amniotics AB's cash to debt ratio for the quarter that ended in Sep. 2023 was No Debt ⁽¹⁾.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Amniotics AB could pay off its debt using the cash in hand for the quarter that ended in Sep. 2023.

(1) Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

The historical rank and industry rank for Amniotics AB's Cash-to-Debt or its related term are showing as below:

OSTO:AMNI' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.24 Med: No Debt Max: No Debt
Current: 0.24

During the past 4 years, Amniotics AB's highest Cash to Debt Ratio was No Debt. The lowest was 0.24. And the median was No Debt.

OSTO:AMNI's Cash-to-Debt is ranked worse than
91.07% of 1535 companies
in the Biotechnology industry
Industry Median: 6.49 vs OSTO:AMNI: 0.24

Amniotics AB Cash-to-Debt Historical Data

The historical data trend for Amniotics AB's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Amniotics AB Cash-to-Debt Chart

Amniotics AB Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Cash-to-Debt

No Debt

0.35

60.08

0.60

Amniotics AB Quarterly Data
	Dec19	Mar20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Jun23	Sep23
Cash-to-Debt	Get a 7-Day Free Trial									No Debt	No Debt	0.60	No Debt	No Debt

Competitive Comparison of Amniotics AB's Cash-to-Debt

For the Biotechnology subindustry, Amniotics AB's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Amniotics AB's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Amniotics AB's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Amniotics AB's Cash-to-Debt falls into.

Amniotics AB Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Amniotics AB's Cash to Debt Ratio for the fiscal year that ended in Dec. 2022 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	9.104	/	(15.067	+	0)
	=	0.60

Amniotics AB's Cash to Debt Ratio for the quarter that ended in Sep. 2023 is calculated as:

Amniotics AB had no debt ⁽¹⁾.

Amniotics AB (OSTO:AMNI) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Amniotics AB Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Amniotics AB's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Amniotics AB (OSTO:AMNI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Amniotics AB (OSTO:AMNI) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

66J:Germany

Address

Scheelevagen 2, Lund, SWE, 223 63

Website

https://www.amniotics.com

Amniotics AB is a biopharma company focusing on mesenchymal stem cells from amniotic fluid. It provides a novel platform for the production of medically superior mesenchymal stem cells including ethical and medically sound bio-banking opportunities for the newborn.